Gene therapy clinical trials for HIV.
Despite advances in drug treatment for human immunodeficiency virus (HIV), new therapeutics are needed for sustained treatment of this infection. Gene therapy has great potential for HIV due to its specificity for viral targets and prolonged expression of therapeutics. In this review, the various approaches that current gene therapy clinical trials are using to treat HIV disease are described. Results reported from these trials indicate that the approaches tested appear to be safe and confer some benefit to the genetically-modified cell. However, technical improvements must be made in order for gene therapy to realize its true potential.
Statham
S
S
Clinical Gene Therapy Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-1851, USA.
Morgan
R A
RA
D019264:Adoptive Transfer; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004200:Diseases in Twins; D005544:Forecasting; D015694:Gene Products, rev / Q000502:physiology; D015757:Genes, rev; D015756:Genes, tat; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use; D006678:HIV / Q000235:genetics / Q000502:physiology; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015658:HIV Infections / Q000628:therapy*; D006412:Hematopoietic Stem Cells / Q000502:physiology; D006801:Humans; D009154:Mutation; D016372:RNA, Antisense / Q000235:genetics; D016337:RNA, Catalytic / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000502:physiology; D012190:Retroviridae / Q000235:genetics; D012449:Safety; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019076:Transgenes; D016662:Virus Integration; D014779:Virus Replication; D054321:rev Gene Products, Human Immunodeficiency Virus
D015694:Gene Products, rev; D015483:HIV Antibodies; D016372:RNA, Antisense; D016337:RNA, Catalytic; D011993:Recombinant Fusion Proteins; C427204:hammerhead ribozyme; D054321:rev Gene Products, Human Immunodeficiency Virus